Formulation and stability of cytokine therapeutics

Journal of Pharmaceutical Sciences

Volumn 104, Issue 2, 2015, Pages 307-326

  Lipiäinen, Tiina ^a   Peltoniemi, Marikki ^a   Sarkhel, Sanjay ^a   Yrjönen, Teijo ^a   Vuorela, Heikki ^a   Urtti, Arto ^a,b   Juppo, Anne ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Biopharmaceuticals characterization; Biosimilar; Excipients; Injectables; Lyophilization; Oxidation; Protein aggregation; Protein formulation; Protein structure; Solid state

Indexed keywords

ALBUMIN; ALPHA INTERFERON; AMINO ACID; BENZYL ALCOHOL; BETA INTERFERON; BUFFER; CARBOHYDRATE; CHLORBUTOL; CITRIC ACID; CYTOKINE; EDETIC ACID; EXCIPIENT; GAMMA INTERFERON; GLYCINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 2; MANNITOL; META CRESOL; METHIONINE; PHENOL; POLOXAMER; POLYMER; POLYSORBATE; POLYSORBATE 80; SODIUM CHLORIDE; SUCROSE; SUGAR; UNINDEXED DRUG;

ALPHA HELIX; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; CONSENSUS SEQUENCE; DEAMINATION; DRUG FORMULATION; FREEZE DRYING; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IONIC STRENGTH; MEGAKARYOPOIESIS; MOLECULAR WEIGHT; NONHUMAN; OXIDATION; PH; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SHELF LIFE; STORAGE; THERMOSTABILITY; THROMBOCYTOPOIESIS; BIOLOGICAL THERAPY; DRUG STABILITY; IMMUNOLOGY; MEDICINAL CHEMISTRY; METABOLISM;

BIOLOGICAL THERAPY; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; DRUG STABILITY; HUMANS;

EID: 84922927350     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24243     Document Type: Review

References (147)

1. Commins SP, Borish L, Steinke JW. 2010. Immunologic messenger molecules: Cytokines, interferons, and chemokines. J Allergy Clin Immun 125:S53-S72.
2. Donnelly RP, Young HA, Rosenberg AS. 2009. An overview of cytokines and cytokine antagonists as therapeutic agents. Ann NY Acad Sci 1182:1-13.
3. Kozlowski S, Cherney B, Donnelly RP. 2009. Hurdles and leaps for protein therapeutics. Ann NY Acad Sci 1182:146-160.
4. Nelles M, Salerno V, Xu Y, Paige C. 2011. Cytokine immunotherapy. In Experimental and applied immunotherapy; Medin J, Fowler D, Eds. New York: Humana Press, pp 281-305.
5. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. 2012. Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135:44-53.
6. Ricci MS, Brems DN. 2004. Common structural stability properties of 4-helical bundle cytokines: Possible physiological and pharmaceutical consequences. Curr Pharm Design 10:3901-3911.
7. Ruiz L, Reyes N, Aroche K, Tolosa V, Simanca V, Rogriguez T, Hardy E. 2005. Influence of packaging material on the liquid stability of interferon-alpha2b. J Pharm Pharm Sci 8:207-216.
8. Gitlin G, Tsarbopoulos A, Patel ST, Sydor W, Pramanik BN, Jacobs S, Westreich L, Mittelman S, Bausch JN. 1996. Isolation and characterization of a monomethioninesulfoxide variant of interferon alpha-2b. Pharm Res 13:762-769.
9. Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, Jiskoot W. 2005. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 22:1997-2006.
10. Torosantucci R, Sharov VS, van Beers M, Brinks V, Schöneich C, Jiskoot W. 2013. Identification of oxidation sites and covalent crosslinks in metal catalyzed oxidized interferon beta-1a: Potential implications for protein aggregation and immunogenicity. Mol Pharm 10:2311-2322.
11. Reyes N, Ruiz L, Aroche K, Geronimo H, Brito O, Hardy E. 2005. Stability of Ala 125 recombinant human interleukin-2 in solution. J Pharm Pharmacol 57:31-37.
12. Reubsaet JL, Beijnen JH, Bult A, Hop E, Scholten SD, Teeuwsen J, Underberg WJ. 1998. Oxidation of recombinant methionyl human granulocyte colony stimulating factor. J Pharm Biomed Anal 17:283-289.
13. Holzmann J, Hausberger A, Rupprechter A, Toll H. 2013. Top-down MS for rapid methionine oxidation site assignment in filgrastim. Anal Bioanal Chem 405:6667-6674.
14. Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schoneich C, Winter G, Friess W, Crommelin DJ, Carpenter JF. 2012. Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci 101:946-954.
15. Singh SK. 2011. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100:354-387.
16. Sauerborn M, Brinks V, Jiskoot W, Schellekens H. 2010. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31:53-59.
17. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8:E501-E507.
18. Casadevall N, Eckardt K-U, Rossert J. 2005. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 16:S67-S69.
19. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. 2001. Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev 46:307-326.
20. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. 2010. Stability of protein pharmaceuticals: An update. Pharm Res 27:544-575.
21. Schiffter HA. 2011. Pharmaceutical proteins - Structure, stability, and formulation. In Comprehensive biotechnology; Moo-Young M, Eds. 2nd ed. Burlington, Vermont: Academic Press, pp 521-541.
22. Topp EM, Zhang L, Zhao H, Payne RW, Evans GJ, Manning MC. 2010. Chemical instability in peptide and protein pharmaceuticals. In Formulation and process development strategies for manufacturing biopharmaceuticals; Jameel F, Hershenson S, Eds. Hoboken, New Jersey: John Wiley & Sons, Inc., pp 41-67.
23. Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. 2012. Forced degradation of therapeutic proteins. J Pharm Sci 101:895-913.
24. Wang W, Nema S, Teagarden D. 2010. Protein aggregation - Pathways and influencing factors. Int J Pharm 390:89-99.
25. Lai MC, Topp EM. 1999. Solid-state chemical stability of proteins and peptides. J Pharm Sci 88:489-500.
26. Jorgensen L, Hostrup S, Moeller EH, Grohganz H. 2009. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - Considerations in the choice of excipients. Expert Opin Drug Deliv 6:1219-1230.
27. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. 2011. Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63:1118-1159.
28. Ohtake S, Wang W. 2014. Protein and peptide formulation development. In Biological drug products: Development and strategies; Wang W, Singh M, Eds. Hoboken, New Jersey: John Wiley & Sons, Inc. p 323-366.
29. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129-188.
30. Wang W. 2000. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203:1-60.
31. Laursen T, Hansen B, Fisker S. 2006. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol 98:218-221.
32. Brassard DL, Grace MJ, Bordens RW. 2002. Interferon-alpha as an immunotherapeutic protein. J Leukocyte Biol 71:565-581.
33. Fuchs SY. 2013. Hope and fear for interferon: The receptor-centric outlook on the future of interferon therapy. J Interf Cytok Res 33:211-225.
34. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. 2004. Mini review human interferons alpha, beta and omega. Growth Factors 22:243-251.
35. Alferon product website. Hemispherx Biopharma Inc. Accessed June 28, 2014, at: http://www.hemispherx.net/content/products/.
36. Blatt LM, Davis JM, Klein SB, Taylor MW. 1996. The biologic activity and molecular characterization of a novel synthetic interferonalpha species, consensus interferon. J Interf Cytok Res 16:489-499.
37. Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. 1997. The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol 274:661-675.
38. Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR. 1996. Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure 4:1453-1463.
39. Bendele A, Seely J, Richey C, Sennello G, Shopp G. 1998. Short communication: Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 42:152-157.
40. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. 2012. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 9:1319-1323.
41. Schellekens H, Hennink WE, Brinks V. 2013. The immunogenicity of polyethylene glycol: Facts and fiction. Pharm Res 30:1729-1734.
42. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, Schreitmuller T. 2003. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expres Purif 30:78-87.
43. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. 2002. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 54:547-570.
44. Adolf GR, Kalsner I, Ahorn H, Maurer-Fogy I, Cantell K. 1991. Natural human interferon-alpha 2 is O-glycosylated. Biochem J 276:511-518.
45. Johnston MJ, Frahm G, Li X, Durocher Y, Hefford MA. 2011. O-linked glycosylation leads to decreased thermal stability of interferon alpha 2b as measured by two orthogonal techniques. Pharm Res 28:1661-1667.
46. Beldarrain A, Cruz Y, Cruz O, Navarro M, Gil M. 2001. Purification and conformational properties of a human interferon alpha2b produced in Escherichia coli. Biotechnol Appl Biochem 33:173-182.
47. Sharma VK, Kalonia DS. 2003. Temperature- and pH-induced multiple partially unfolded states of recombinant human interferon-alpha2a: Possible implications in protein stability. Pharm Res 20:1721-1729.
48. Li Y, Stafford WF, Hesselberg M, Hayes D, Wu Z, Byrne M. 2012. Characterization of the self-association of human interferon-alpha2b, albinterferon-alpha2b, and pegasys. J Pharm Sci 101:68-80.
49. Gross G, Del Terzo S, Kumar SK. 1998. Stabilized interferon alpha solutions. Patent US5762923 A.
50. Ohtake S, Kita Y, Arakawa T. 2011. Interactions of formulation excipients with proteins in solution and in the dried state. Adv Drug Deliv Rev 63:1053-1073.
51. Jeyachandran YL, Mielczarski E, Rai B, Mielczarski JA. 2009. Quantitative and qualitative evaluation of adsorption/desorption of bovine serum albumin on hydrophilic and hydrophobic surfaces. Langmuir 25:11614-11620.
52. Ruiz L, Reyes N, Duany L, Franco A, Aroche K, Hardy Rando E. 2003. Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin. Int J Pharm 264:57-72.
53. Graf E, Mahoney JR, Bryant RG, Eaton JW. 1984. Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J Biol Chem 259:3620-3624.
54. Cindric M, Galic N, Vuletic M, Klaric M, Drevenkar V. 2006. Evaluation of recombinant human interferon alpha-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal 40:781-787.
55. European Medicines Agency. 2005. PegIntron: EPAR - Scientific discussion. Accessed June 28, 2014, at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific.Discussion/human/000280/WC500039385.pdf.
56. European Medicines Agency. 2005. Pegasys: EPAR - Scientific discussion. Accessed June 28, 2014: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000395/WC500039192.pdf.
57. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. 1997. The crystal structure of human interferon beta at 2.2 - A resolution. Proc Natl Acad Sci USA 94:11813-11818.
58. Conradt HS, Egge H, Peter-Katalinic J, Reiser W, Siklosi T, Schaper K. 1987. Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. J Biol Chem 262:14600-14605.
59. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15:641-649.
60. Karpusas M, Whitty A, Runkel L, Hochman P. 1998. The structure of human interferon-beta: Implications for activity. Cell Mol Life Sci 54:1203-1216.
61. Hawe A, Friess W. 2008. Development of HSA-free formulations for a hydrophobic cytokine with improved stability. Eur J Pharm Biopharm 68:169-182.
62. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. 2010. Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res 27:1812-1824.
63. Webb SD, Cleland JL, Carpenter JF, Randolph TW. 2002. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: Slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20. J Pharm Sci 91:543-558.
64. Costantino HR. 2004. Excipients for use in lyophilized pharmaceutical peptide, protein, and other bioproducts. In Lyophilization of bio-pharmaceuticals; Costantino HR, Pikal MJ, Eds. Arlington, Virginia: AAPS Press, pp 139-228.
65. Kasper JC, Friess W. 2011. The freezing step in lyophilization: Physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur J Pharm Biopharm 78:248-263.
66. Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E, Freedman MS, Stuart W, Cunha L, Jacobs L, Oger J, Arnold D, Murray TJ, DiBiase M, Jethwa V, Goelz S. 2004. A multi-center, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 26:511-521.
67. Kim HJ, Shin CH, Kim CW. 2009. Stabilization of glycoprotein liquid formulation using arginine: A study with lactoferrin as a model protein. Biosci Biotechnol Biochem 73:61-66.
68. Arakawa T, Tsumoto K. 2003. The effects of arginine on refolding of aggregated proteins: Not facilitate refolding, but suppress aggregation. Biochem Biophys Res Commun 304:148-152.
69. Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, Antonelli M. 2007. The Rebif new formulation story: It's not trials and error. Drugs R&D 8:335-348.
70. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. 2011. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 28:2393-2402.
71. Zheng X, WuSL, Hancock WS. 2006. Glycationofinterferon-beta-1b and human serum albumin in a lyophilized glucose formulation. Part III: Application of proteomic analysis to the manufacture of biological drugs. Int J Pharm 322:136-145.
72. Farrar MA, Schreiber RD. 1993. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11:571-611.
73. Miller CH, Maher SG, Young HA. 2009. Clinical use of interferongamma. Ann NY Acad Sci 1182:69-79.
74. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferon-gamma: An overview of signals, mechanisms and functions. J Leukocyte Biol 75:163-189.
75. Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, Bugg CE. 1991. Three-dimensional structure of recombinant human interferon-gamma. Science 252:698-702.
76. Arakawa T, Hsu YR, Yphantis DA. 1987. Acid unfolding and self-association of recombinant Escherichia coli derived human interferon gamma. Biochemistry 26:5428-5432.
77. Goossens K, Haelewyn J, Meersman F, De Ley M, Heremans K. 2003. Pressure- and temperature-induced unfolding and aggregation of recombinant human interferon-gamma: A Fourier transform infrared spectroscopy study. Biochem J 370:529-535.
78. Lam XM, Costantino HR, Overcashier DE, Nguyen TH, Hsu CC. 1996. Replacing succinate with glycolate buffer improves the stability of lyophilized interferon-γ. Int J Pharm 142:85-95.
79. Lam XM, Patapoff TW, Nguyen TH. 1997. The effect of benzyl alcohol on recombinant human interferon-gamma. Pharm Res 14:725-729.
80. Malek TR. 2008. The biology of interleukin-2. Annu Rev Immunol 26:453-479.
81. Shaker MA, Younes HM. 2009. Interleukin-2: Evaluation of routes of administration and current delivery systems in cancer therapy. J Pharm Sci 98:2268-2298.
82. Robb RJ, Kutny RM, Panico M, Morris HR, Chowdhry V. 1984. Amino acid sequence and post-translational modification of human interleukin 2. Proc Natl Acad Sci USA 81:6486-6490.
83. Bazan JF. 1992. Unraveling the structure of IL-2. Science 257:410-413.
84. Brandhuber BJ, Boone T, Kenney WC, McKay DB. 1987. Three-dimensional structure of interleukin-2. Science 238:1707-1709.
85. Proleukin® (aldesleukin) label. 2011. Prometheus Laboratories Inc. Available from Drugs@FDA, the database for FDA-approved drug products. Accessed June 28, 2014, at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
86. Hora M. 2006. Preparing aldesleukin for pharmaceutical use. Patent EP1688146 (A1).
87. Ricci MS, Sarkar CA, Fallon EM, Lauffenburger DA, Brems DN. 2003. pH dependence of structural stability of interleukin-2 and granulocyte colony-stimulating factor. Protein Sci 5:1030-1038.
88. Prestrelski SJ, Pikal KA, Arakawa T. 1995. Optimization of lyophilization conditions for recombinant human interleukin-2 by dried-state conformational analysis using Fourier-transform infrared spectroscopy. Pharm Res 12:1250-1259.
89. Ontak® (denileukin difttox) label. 2011. Eisai Inc. Available from Drugs@FDA, the database for FDA-approved drug products. Accessed June 28, 2014, at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
90. Du XX, Williams DA. 1994. Interleukin-11: A multifunctional growth factor derived from the hematopoietic microenvironment. Blood 83:2023-2030.
91. Czupryn MJ, McCoy JM, Scoble HA. 1995. Structure-function relationships in human interleukin-11: Identification of regions involved in activity by chemical modification and site-directed mutagenesis. J Biol Chem 270:978-985.
92. Du X, Williams DA. 1997. Interleukin-11: Review of molecular, cell biology, and clinical use. Blood 89:3897-3908.
93. Adams VR, Brenner TL. 1999. Oprelvekin (Neumega®). J Oncol Pharm Pract 5:117-124.
94. Page C, Dawson P, Woollacott D, Thorpe R, Mire-Sluis A. 2000. Development of a lyophilization formulation that preserves the biological activity of the platelet-inducing cytokine interleukin-11 at low concentrations. J Pharm Pharmacol 52:19-26.
95. Neumega® (oprelvekin) label. 2009. Wyeth Pharmaceuticals Inc. Available from Drugs@FDA, the database for FDA-approved drug products. Accessed June 28, 2014, at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
96. Takagi A, Masuda H, Takakura Y, Hashida M. 1995. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J Pharmacol Exp Ther 275:537-543.
97. Gokarn YR, Kosky A, Kras E, McAuley A, Remmele RL Jr. 2006. Excipients for protein drugs. In Excipient development for pharmaceutical, biotechnology, and drug delivery systems; Katdare A, Chaubal MV, Eds. New York: Informa Healthcare USA, Inc., pp 291-332.
98. Garzon-Rodriguez W, Koval RL, Chongprasert S, Krishnan S, Randolph TW, Warne NW, Carpenter JF. 2004. Optimizing storage stability of lyophilized recombinant human interleukin-11 with disaccharide/hydroxyethyl starch mixtures. J Pharm Sci 93:684-696.
99. Wadhwa M, Thorpe R. 2008. Haematopoietic growth factors and their therapeutic use. Thromb Haemost 99:863-873.
100. Kubota N, Orita T, Hattori K, Oh-eda M, Ochi N, Yamazaki T. 1990. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem 107:486-492.
101. Wingfield P, Benedict R, Turcatti G, Allet B, Mermod JJ, DeLamarter J, Simona MG, Rose K. 1988. Characterization of recombinantderived granulocyte-colony stimulating factor (G-CSF). Biochem J 256:213-218.
102. Hill CP, Osslund TD, Eisenberg D. 1993. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci USA 90:5167-5171.
103. Lonquex Product Information. 2014. Sicor Biotech UAB, Teva Pharmaceuticals Europe. Available from the European Medicines Agency database of medicines. Accessed June 28, 2014, at: http://www.ema.europa.eu/ema/
104. Mahlert F, Schmidt K, Allgaier H, Liu P, Müller U, Shen WD. 2013. Rational development of lipegfilgrastim, a novel long-acting granulocyte colony-stimulating factor, using glycopegylation technology. Blood 122:4853-4853.
105. Krishnan S, Chi EY, Webb JN, Chang BS, Shan D, Goldenberg M, Manning MC, Randolph TW, Carpenter JF. 2002. Aggregation of granulocyte colony stimulating factor under physiological conditions: Characterization and thermodynamic inhibition. Biochemistry 41:6422-6431.
106. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW. 2003. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12:903-913.
107. Yamazaki K, Murayama K, Ishikawa R, Ozaki Y. 2005. An infrared spectroscopy study of acid stability and thermal unfolding process of granulocyte-colony stimulating factor. J Biochem 137:265-271.
108. Thirumangalathu R, Krishnan S, Brems DN, Randolph TW, Carpenter JF. 2006. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci 95:1480-1497.
109. Oh-eda M, Hasegawa M, Hattori K, Kuboniwa H, Kojima T, Orita T, Tomonou K, Yamazaki T, Ochi N. 1990. O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 265:11432-11435.
110. Lu HS, Fausset PR, Narhi LO, Horan T, Shinagawa K, Shimamoto G, Boone TC. 1999. Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: Effect on stability and biological activity. Arch Biochem Biophys 362:1-11.
111. Yin J, Chu JW, Ricci MS, Brems DN, Wang DI, Trout BL. 2004. Effects of antioxidants on the hydrogen peroxide-mediated oxidation of methionine residues in granulocyte colony-stimulating factor and human parathyroid hormone fragment 13-34. Pharm Res 21:2377-2383.
112. Sörgel F, Lerch H, Lauber T. 2010. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. Biodrugs 24:347-357.
113. Ha E, Wang W, Wang YJ. 2002. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 91:2252-2264.
114. Committee for Medicinal Products for Human Use (CHMP) assessment report for Zarzio. 2008. European Medicines Agency. EMEA/CHMP/651339/2008. Accessed June 28, 2014, at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/000917/WC500046528.pdf
115. Piedmonte DM, Treuheit MJ. 2008. Formulation of Neulasta (pegfilgrastim). Adv Drug Deliv Rev 60:50-58.
116. Martin-Christin F. 2001. Granulocyte colony stimulating factors: How different are they? How to make a decision? Anti-cancer drug 12:185-191.
117. Fournier-Broggini E. 2001. Stability studies of a new formulation of glycosylated rHuG-CSF (lenograstim), stable at room temperature for 2 years. Bone Marrow Transpl 27:S164-S164.
118. Granocyte (lenograstim) data sheet. 1998. Chugai Pharmaceuticals Co, Ltd, AMRAD Pharmaceuticals Pty Ltd. MEDSAFE, New Zealand Medicines and Medical Devices Safety Authority. Accessed June 28, 2014, at: http://www.medsafe.govt.nz/profs/datasheet/g/Granocyteinj.htm.
119. Stevenson C, Hastedt JE, Lehrman SR, Chiang H-S, Bennett DB, Lesikar D, Yang B, Gong D, Cabot K. 2002. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation. International patent WO2002011695 A2.
120. Mattern M, Winter G, Kohnert U, Lee G. 1999. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. Pharm Dev Technol 4:199-208.
121. Wingfield P, Graber P, Moonen P, Craig S, Pain RH. 1988. The conformation and stability of recombinant-derived granulocytemacrophage colony stimulating factors. Eur J Biochem 173:65-72.
122. Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P. 2004. Immunogenicity of interferon beta: Differences among products. J Neurol 251:II15-II24.
123. Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D. 2006. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjugate Chem 17:618-630.
124. Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G. 2012. A novel PEGylated interferon beta-1a for multiple sclerosis: Safety, pharmacology, and biology. J Clin Pharmacol 52:798-808.
125. Biogen Idec product pipeline. 2014. Accessed June 28, 2014, at: http://www.biogenidec.com/research-product-pipeline.aspx?ID=5778.
126. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14:1472-1478.
127. Chou DK, Krishnamurthy R, Manning MC, Randolph TW, Carpenter JF. 2012. Physical stability of albinterferon-alpha(2b) in aqueous solution: Effects of conformational stability and colloidal stability on aggregation. J Pharm Sci 101:2702-2719.
128. Foureau D, Vrikkis R, Jones C, Weaver K, MacFarlane D, Salo J, McKillop I, Elliott G. 2012. In vitro assessment of choline dihydrogen phosphate (CDHP) as a vehicle for recombinant human interleukin-2 (rhIL-2). Cel Mol Bioeng 5:390-401.
129. Jhunjhunwala S, Balmert SC, Raimondi G, Dons E, Nichols EE, Thomson AW, Little SR. 2012. Controlled release formulations of IL-2, TGF-beta1 and rapamycin for the induction of regulatory T cells. J Control Release 159:78-84.
130. Takagi A, Yamashita N, Yoshioka T, Takaishi Y, Nakanishi K, Takemura S, Maeda A, Saito K, Takakura Y, Hashida M. 2006. Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human interleukin 11 (rhIL11). J Control Release 115:134-139.
131. Takagi A, Yamashita N, Yoshioka T, Takaishi Y, Sano K, Yamaguchi H, Maeda A, Saito K, Takakura Y, Hashida M. 2007. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol. J Control Release 119:271-278.
132. Jung Y, Ahn H, Kim D-S, Hwang YR, Ho S-H, Kim J-M, Kim S, MaS, KimS. 2011. Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis. Biochem Biophys Res Commun 405:399-404.
133. Gasmi N, Lassoued R, Ayed A, Treton B, Chevret D, Nicaud JM, Kallel H. 2012. Production and characterization of human granulocyte-macrophage colony-stimulating factor (hGM-CSF) expressed in the oleaginous yeast Yarrowia lipolytica. Appl Microbiol Biotechnol 96:89-101.
134. Ceaglio N, Etcheverrigaray M, Kratje R, Oggero M. 2010. Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein. Biochimie 92:971-978.
135. Kumar V, Sharma VK, Kalonia DS. 2009. In situ precipitation and vacuum drying of interferon alpha-2a: Development of a singlestep process for obtaining dry, stable protein formulation. Int J Pharm 366:88-98.
136. Bristol-Myers Squibb pipeline. 2014. Accessed June 28, 2014, at: http://www.bms.com/research/pipeline/Pages/default.aspx.
137. Merck Serono pipeline. 2014. Accessed June 28, 2014, at: http://www.merckserono.com/en/research-development/pipeline/pipeline.html.
138. Roche pipeline. 2014. Accessed June 28, 2014, at: http://www.roche.com/research-and-development/who-we-are-how-we-work/pipeline.htm.
139. Pfizer pipeline. 2014. Accessed June 28, 2014, at: http://www.pfizer.com/research/science-and-technology/product-pipeline.
140. Shi ZT, Lin Y, Wang J, Wu J, Wang RF, Chen FQ, Mi WJ, Qiu JH. 2013. G-CSF attenuates noise-induced hearing loss. Neurosci Lett 6:102-106.
141. Fortunato G, Vidal DTA, Klein W, Neto A, Angrizani A, Vasconcelos JF, Kaneto C, Souza BSdF, Ribeiro-dos-Santos R, Soares MBP, Macambira SG. 2013. Recovery of pulmonary structure and exercise capacity by treatment with granulocyte-colony stimulating factor (G-CSF) in a mouse model of emphysema. Pulm Pharmacol Ther 27:144-149.
142. Favors SE, Curd LM, Gregg RK. 2012. Use of the anti-inflammatory cytokine interleukin-11 to reverse HIV-1gp120 repression of a natural killer cell line. Cell Immunol 276:1-5.
143. Ruiz L, Rodriguez I, Baez R, Aldana R. 2007. Stability of an extemporaneously prepared recombinant human interferon alfa-2b eye drop formulation. Am J Health Syst Pharm 64:1716-1719.
144. Francisco-Cruz A, Aguilar-Santelises M, Ramos-Espinosa O, Mata-Espinosa D, Marquina-Castillo B, Barrios-Payan J, Hernandez-PandoR.2014. Granulocyte-macrophage colony-stimulating factor: Not just another haematopoietic growth factor. Med Oncol 31:774.
145. Label information. Drugs@FDA. Database for FDA Approved Drug Products. FDA Center for Drug Evaluation and Research. 2014. Accessed June 28, 2014, at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
146. Product information. Search for medicines. Databaseofmedicines. European Medicines Agency. 2014. Accessed June 28, 2014, at: http://www.ema.europa.eu/ema/.
147. Information on medicinal products. FimeaWeb search. Finnish Medicines Agency. 2014. Accessed June 28, 2014, at: http://www.fimea.fi/laaketieto/laakehaku.